A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial von Boyd, K D, Ross, F M, Chiecchio, L, Dagrada, G P, Konn, Z J, Tapper, W J, Walker, B A, Wardell, C P, Gregory, W M, Szubert, A J, Bell, S E, Child, J A, Jackson, G H, Davies, F E, Morgan, G J

Volltext

P+R‐ICE: PEMBROLIZUMAB IN COMBINATION WITH R‐ICE CHEMOTHERAPY IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA ‐ ONGOING TRIAL von Stanton, L., Cole, A., Keyworth, N., Collins, G. P, McKay, P., Smith, P., Radhakrishnan, V., Konn, Z., Irvine, N., Coleman, A., Stuart, C., Hatchard, P., Longman, K., Philip, D. M., Caddy, J., Davies, A. J

Volltext

Determinants of response to T‐cell stimulation by CD27 antibody therapy in lymphoma: The RiVa trial von Rose‐Zerilli, M. J., Buermann, L., Stanton, L., Wignall, C. M., Coleman, A. R., Thorne, K., Keyworth, N., Konn, Z., Turaj, A. H., McKay, P., Osborne, W., Linton, K., Medd, P., Collins, G. P., Keler, T., Yellin, M., Gentles, A., Griffiths, G., Lim, S. H.

Volltext

Long-term follow-up of ETV6–RUNX1 ALL reveals that NCI risk, rather than secondary genetic abnormalities, is the key risk factor von Enshaei, A, Schwab, C J, Konn, Z J, Mitchell, C D, Kinsey, S E, Wade, R, Vora, A, Harrison, C J, Moorman, A V

Volltext

Disruption of ETV6 in intron 2 results in upregulatory and insertional events in childhood acute lymphoblastic leukaemia von Jalali, G R, An, Q, Konn, Z J, Worley, H, Wright, S L, Harrison, C J, Strefford, J C, Martineau, M

Volltext

Haploinsufficiency of the MLL and TOB2 genes in lymphoid malignancy von An, Q, Burke, G A A, Dainton, M, Harrison, C J, Kempski, H, Konn, Z, Myooren, W, Stewart, A, Taj, M, Webb, D, Strefford, J C, Martineau, M

Volltext

Rö: Kay: Mtt: Instruction vnd Ordnung auff derselben ZollEinnember vnd Gegenhandler in der Cron Behem. Anno M. DC. VIII von Rudolf II. Habsburský, římskoněmecký císař, jn20000701541

Volltext bestellen